| Identification | Back Directory | [Name]
PCI-27483 | [CAS]
871266-63-6 | [Synonyms]
CS-1599
PCI-27483
PCI27483/PCI-27483
PCI27483;PCI-27483;PCI 27483
(S)-2-[[2-[5-(5-Carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetyl]amino]succinic acid
(S)-2-(2-(5-(5-carbamimidoyl-1H-benzo[d]imidazol-2-yl)-2',6-dihydroxy-5'-sulfamoylbiphenyl-3-yl)acetamido)succinic acid
L-Aspartic acid, N-[2-[5-[6-(aminoiminomethyl)-1H-benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]acetyl] | [Molecular Formula]
C26H24N6O9S | [MDL Number]
MFCD25976837 | [MOL File]
871266-63-6.mol | [Molecular Weight]
596.57 |
| Chemical Properties | Back Directory | [density ]
1.74±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:10.0(Max Conc. mg/mL);16.8(Max Conc. mM) | [form ]
A crystalline solid | [pka]
2.74±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
PCI-27483 is a small-molecule inhibitor of activated factor VII with antineoplastic and anti-thrombotic activity. | [in vivo]
PCI-27483 shows dose-dependent inhibition of thrombus formation, fibrin accumulation and PT. PCI-27483 (4 mg/kg) shows comparable anticoagulation effects as 2 mg/kg enoxaparin[1]. PCI-27483 (0 and 90 mg/kg, s.c.) results in inhibition of tumor growth in CD1 nu/nu mice implanted with BxPC3 cells[2]. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0.htm |
|